J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

On Tuesday, Kymera Therapeutics shares leaped 12% following the biotechnology firm's update on its product pipeline. The New York-based company announced progress in its programs for atopic dermatitis ...

Groundbreaking therapies for inflammatory diseases, ambitious clinical milestones, and a cash-rich balance sheet fuel investor confidence.

Kymera Therapeutics (KYMR) stock surged as the company outlined its 2025 outlook at the J.P. Morgan Healthcare Conference. Read more here.

Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative ...